The HLA restriction and epitope specificity of cytotoxic T lymphocytes ( 
Introduction
Each year the vaccine for influenza is updated to include the recognized by cytotoxic T lymphocytes (CTL) could contribute to the development of vaccines aimed at specifically generatmost current circulating strains of influenza type A and B viruses (1). Influenza type A is more heavily studied because ing CTL immunity. CTL recognize viral peptides in the peptide-binding site of it is the cause of pandemics. However, influenza type B frequently predominates in yearly influenza surveys. In the HLA molecules (20, 21) . Early CTL studies focusing on a single class I HLA molecule implied a CD8 CTL response US, influenza type B epidemics occurred in approximately seven out of the last 15 years, including the winters of 1988-directed against one dominant peptide. However, studies on the CTL response to HIV epitopes presented by HLA-B8 89, 1990-91 and 1992-93 (2-6). Complications arising from influenza type B infections include Reye's syndrome, respirat- (22, 23) suggest that multiple epitopes presented by a single HLA molecule compete for antigenic stimulation (24) . One ory failure, fatal rhabdomyolysis and encephalitis (7-10). While a major source of antigenic diversification in influenza HLA-A2-restricted CD8 CTL epitope has been previously defined from influenza type B nucleoprotein (25, 26) . Here a type A is animal reservoirs, there are no animal reservoirs for influenza type B virus. Periodic epidemics of influenza type broad CTL response composed of both CD8 CTL and CD4 CTL is demonstrated to influenza type B virus. Studies with B virus appear to result from the accumulation of mutations selected by antibody-mediated immune pressure and cowhole virus indicated that most of the class I and class II HLA molecules expressed in the individual studied (HLA type: circulation of distinct lineages of virus (6, (11) (12) (13) (14) (15) (16) (17) (18) (19) . Serological diversity due to changes in amino acid sequence is the major HLA-A1, A2, B7, B8, Cw7, DR1, DR3, DQw2, DQ5) presented viral CTL epitopes. Bulk CTL recognized four peptide epitopes obstacle to effective vaccination against influenza B virus using the current killed vaccines that target B cell antibody predicted by known allele-specific motifs for peptides interacting with HLA-B8 and HLA-DR1. Peptides 30-38 and 263-responses. Identifying conserved epitopes in influenza B virus (25, 27) priming, according to the manufacturer's instructions to prepare cDNA from total cellular RNA (1 µg per 20 µl reaction). were expanded in 143 B thymidine kinase minus human osteosarcoma cells (ATCC). The number of p.f.u./ml were DNA was isolated from Ficoll-Hypaque isolated PBMC by a standard SDS-proteinase K digestion technique. A 641 bp determined on BSC-1 cells (ATCC). Viral peptides based on the sequences of nucleoprotein B/AA/86 (27) , B/Lee/40 (28) PCR product was generated using oligonucleotide primers from the 5Ј region (GGA TTC CAG CTC CAT GGC AG) and and hemagglutinin B/HK/73 (13) were synthesized by the CBER Peptide Facility (Bethesda, MD), Tana Laboratories from the complement of the 3Ј region (GCT GGG TGG AGG CGT TGA AG) spanning two introns in the coding sequence (Houston, TX) and Bio-Synthesis (Lewisville, TX). The molecular mass of peptides was checked by mass spectroscopy.
of the human perforin gene (29) . A 536 bp DNA competitive reference standard for this amplicon was prepared by the Peptides were preincubated with target cells at 100 µg/ml. The nucleotide sequences of the nucleoprotein genes of the deletion method of Riedy et al. (30) using a 3Ј region deletion primer (GGC GGG CTG GGT GGA GGC GTT GAA CCT GGT recent influenza B isolates, B/YM-88 and B/TX-88, were derived by direct sequencing of purified viral RNA as previ-CCT GGT GGG TCT TCT). A 35 cycle, hot start PCR was performed on samples containing a fixed amount of cDNA ously described (18). Sequencing primers were constructed based on the nucleoprotein sequence of B/AA/86 (27) . The and a series of 2-fold dilutions of reference standard, as per instructions in the GeneAmp kit (Perkin-Elmer Cetus, complete sequences of the nucleoprotein genes of B/TX and B/YM have been deposited at the Genome Sequence Data Branchburg, NJ) as modified by the manufacturer's instructions accompanying the AmpliWax beads (Perkin-Elmer Base under accession nos L49384 and L49385 respectively. Cetus). Optimum amplification of these amplicons was CTL, target cells and CTL assay obtained with a reaction mix containing 0.75 mM MgCl 2 and PCR cycles consisting of a 1 min denaturation step (94°C) The HLA type of the CTL and target cells used in these experiments are shown in Table 1 . For generation of CTL and and a 1 min annealing step at 63°C followed by a 2.5 min B8 and Cw7. Thus, at minimum four class I HLA molecules, HLA-A1, HLA-A2, HLA-B7 and HLA-B8 and/or Cw7 presented peptide epitopes from influenza type B virus. To determine if there was a class II-restricted CTL response to the virus, target cells sharing one or more class II HLA molecules with the donor were used (Table 1) . Polyclonal CTL recognized HOM-2 cells infected with virus above that of cells uninfected (Fig. 3A) . HOM-2 cells share HLA-DR1 and HLA-DQ5 with the effector CTL. To determine whether HLA-DR1 could present virus, polyclonal CTL were assayed for lysis of mouse C3H L cells transfected with HLA-DR1 infected and uninfected with B/HK/73 virus. CTL lysed L cells infected with virus, but not uninfected L cells (Fig. 3B) . CTL also killed MLB cells infected with virus above that of uninfected MLB HLA-DQ5 and DQw2.
Influenza virus expresses 10 proteins of which nucleoprotein, an abundant protein made during virus infection, is known to be a common target antigen for class I-restricted CTL (32) . To determine whether viral nucleoprotein peptides were extension step (72°C). A 597 bp PCR product was generated using oligonucleotide primers from the 5Ј region (TTC CCT presented by HLA-B molecules, polyclonal CTL were tested for recognition of target cells infected with wild-type vaccinia GTC CAA CCT CTG TG) and from the complement of the 3Ј region (TCT TCC CCT CCA TCA TCA CC) spanning three virus and recombinant vaccinia virus expressing influenza B/ AA/86 nucleoprotein. Polyclonal CTL recognized MGAR cells introns in the coding sequence of the human Fas ligand gene (31) . Optimum amplification of this amplicon was obtained in expressing type B nucleoprotein above MGAR cells infected with wild-type vaccinia virus (Fig. 4A ), but had no recognition a 40 cycle PCR, annealing at 60°C with a reaction mix containing 0.75 mM MgCl 2 . Amplified products were subof nucleoprotein presented by PGF cells (Fig. 4A) . Thus, HLA-B8 and/or HLA-Cw1 presented a peptide or peptides derived jected to electrophoresis in a 2% (w/v) agarose gel containing 0.5 mg/ml ethidium bromide. After electrophoresis, videofrom nucleoprotein, while the peptides presented by HLA-B7 must derive from other viral proteins. Recognition of HLA-B8 images of PCR products were obtained with the UVP 5100 Gel Documentation System (UVP, San Gabriel, CA) and could not be separated from HLA-Cw7 because the B8 haplotype in almost all instances is fixed in the HLA-B to densitometric analysis of the quantity of PCR products was performed with NIH Image 1.55 software. The molar concen-DQ region. The allele-specific motif for peptides interacting with HLAtration of perforin mRNA in the samples was calculated by plotting the concentration of added reference standard versus B8 is known. These peptides often have an arginine (R) or lysine (K) in positions 3 and 5 and a leucine or isoleucine in the ratio of the band densities and determining the point of equivalence (30) . position 9 (33, 34) . Defined CTL epitopes also reveal that isoleucine (I), leucine (L) or glutamine (Q) can be present at residues 3 or 5 (22, 35, 36) . Examination of the amino acid Results sequence of influenza B/AA/86 nucleoprotein identified 28 possible peptides with residue R, K, L, I or Q at P3 and P5. To determine whether the donor had memory CTL to influenza type B virus, peripheral blood mononuclear cells were stimuSix peptides were chosen for synthesis based on their Cterminal residue. Five of the 28 sequences had a leucine or lated with influenza B/HK/73 or influenza B/AA/1986 and tested 5 days later for detection of polyclonal CTL activity.
isoleucine at P8 or P9, and one had valine at P9. Two 9mer peptides 30-38 (RPIIRPATL) and 263-271 (ADRGLLRDI) were CTL lysed autologous B lymphoblasts infected with either virus above that of uninfected cells, and did not lyse HLArecognized by polyclonal CTL above background (Fig. 4B) , while two 9mer peptides, 536-544 (SDKNKTNPI) and 481-489 mismatched cells, MANN, either infected with B/HK/73 or uninfected (Fig. 1) .
(VRRMLSMNI), and one 8mer peptide, 377-384 (DAKDKSQL), were not recognized by polyclonal CTL above background The class I HLA restriction of the response was determined using target cells sharing one or more class I HLA molecules ( Fig. 4B and data not shown) . The high non-antigen specific lysis could be due to NK or Epstein-Barr virus reactivity. The with effector CTL (see Table 1 ). Polyclonal CTL lysed B/HK/ 73-infected PR B lymphoblasts sharing HLA-A1 ( Fig. 2A) and 9mer peptide, 413-422 (ALKCKGFHV), was recognized at a K:T ratio of 50:1 (Fig. 4B) and sporadically recognized at AT B lymphoblasts B/HK/73-infected sharing HLA-A2 (Fig. 2B) better than uninfected cells. Polyclonal CTL also lower K:T ratios (data not shown), but repeated attempts to consistently stimulate growth of a CTL line using this peptide lysed B/HK/73-infected MGAR (Fig. 2C) and B/HK/73-infected PGF B lymphoblasts (Fig. 2D) better than uninfected cells.
failed. CTL lines established on peptides 30-38 ( Fig. 4C ) and 263-271 (Fig. 4D ) recognized both influenza type B virus-PGF shares HLA-B7 with the CTL, while MGAR shares HLA-infected and peptide-pulsed cells. The CTL line established with peptide 30-38 also recognized peptide 30-38(34K), the nucleoprotein amino acid sequence of the B/Lee/40 virus that has lysine instead of arginine at residue 34 (Fig. 4E) .
In general, many of the peptides presented by class II HLA molecules derive from glycoproteins (37) . Influenza B virus makes two glycosylated proteins, neuraminidase and hemagglutinin. In influenza type A virus, class II HLA molecules present peptides from these proteins (38) (39) (40) . For peptides bound to HLA-DR1, tyrosines at position 1 (P1) of a core 9mer peptide and the third position from the N-terminus provide the primary anchor residues (41, 42) . Important secondary interactions occur at amino acid residues P4, P6 and P9 from the P1 tyrosine (42) . Influenza B/HK/73 hemagglutinin had 12 possible peptide epitopes with tyrosine in the correct position. Of these possible epitopes, a 13mer peptide, residues 308-320, PYYTGEHAKAIGN, had the most compatible amino acid residues for the best secondary interactions with an alanine at P6 and an isoleucine at P9 (42) . Polyclonal CTL lysed autologous (Fig. 5A ) and HOM-2 B lymphoblasts (data not shown) pulsed with peptide 308-320 above that of target cells without peptide. A CTL line grown from these polyclonal CTL stimulated with peptide 308-320 recognized peptide 308-320 and influenza B virus presented on HOM-2 B lymphoblasts (Fig. 5B ) and presented on autologous B lymphoblasts (data not shown). FACS analysis indicated this line was 85% CD4 ϩ (data not shown). An anti-HLA-DR mAb (L234), but not anti-HLA class I mAb (clone W6/32), inhibited recognition of the HA peptide 308-320 by this CTL line (Fig. 5C) . The CTL line used in experiment Fig. 5(C) done at a later date after more re-stimulation with peptide contained 100% CD4 ϩ cells by FACS analysis (data not shown). A clone was isolated by limiting dilution from the hemagglutinin peptide-specific CTL line. FACS analysis indicated that this clone expressed CD4, not CD8 (data not shown). The clone lysed autologous target cells incubated with peptide 308-320 (Fig. 5D) .
The CD4 CTL clone expressed perforin mRNA and Fas ligand mRNA (Fig. 6A) . Quantitative-competitive PCR was performed to determine the level of perforin mRNA expressed in the CTL clone. From a plot of the data shown in Fig. 6(B) the point of equivalence is at 0.5 am for 2ϫ10 -3 µg total RNA; this calculates to be~200 molecules of perforin mRNA/cell.
Discussion
The CTL response to influenza type B in one individual was examined in detail. A broad polyclonal response composed of both CD8 CTL and CD4 CTL to influenza type B was detectable after one in vitro stimulation and expansion of memory CTL by co-culture with virus. A minimum of five defined epitopes were recognized by bulk CTL; three peptide epitopes, 30-38, 262-271 and 413-421, from nucleoprotein presented by HLA-B8, one peptide epitope presented HLA-DR1 from hemagglutinin, 308-320, and an additional nucleoprotein epitope, 82-95, presented by HLA-A2 previously defined (25 and data not shown). Bulk CTL responses restricted by HLA-A1, B7 and DR3 indicate three additional epitopes bringing the minimum number of epitopes recognized by these polyclonal CTL to eight. Although the relative immunodominance among these epitopes was not determined, the CTL response appears directed against multiple epitopes and not a single epitope, since all of the epitopes indicated or defined were recognized by bulk CTL.
From the bulk CTL response it was apparent that among the epitopes presented by HLA-B8, CTL against nucleoprotein epitope 413-421 were less frequent than those against nucleoprotein epitopes 30-38 and 262-271. Moreover, of the six epitopes containing HLA-B8 binding motifs tested, only 30-38 and 262-271 were well recognized by bulk CTL. Peptide 413-421 was recognized only at the highest CTL concentration, while 377-389, 481-489 and 536-544 were not at all recognized, although all peptides had a HLA-B8 binding motif. The predicted 8mer peptide 377-389 might have been excluded from CTL recognition by its suboptimal length, which could favor the formation of unstable HLA molecules (26) . Antigen-processing mechanisms, binding affinities or CTL repertorie must have favored CTL recognition of peptides 30-38 and 262-271 over peptides 413-421, 481-489 and 536-544.
Amino acid sequences of influenza type B nucleoprotein and hemagglutinin from different virus isolates were examined to determine whether the newly defined peptide epitopes were type, subtype or strain specific. The CTL epitope 263-271 from nucleoprotein presented by HLA-B8 was conserved among distinct influenza type B strains Lee/40, AA/86, SN/79, TX/88 and YM/88 differing in other parts of their nucleoprotein sequence (27, 28, 43) . This epitope is conserved over time and conserved in viruses of distinct type B lineages, TX/ 88 and YM/88 (6,18,19). In the viral isolate B/Lee/40, the nucleoprotein residues 30-38 have a lysine at residue 34 (28) , while SN/79, AA/86, TX/88 and YM/88 isolates have an arginine (27, 28, 43) . However, either lysine or arginine serve as major anchor residues at P5 (which is residue 34 in the 30-38 peptide) for peptides binding to HLA-B8 (33,34) and consequently may not affect TCR recognition. Furthermore, the B/Lee/40 virus has not circulated since 1940 and was passaged extensively in mice before amino acid sequencing. Thus, although the epitope 30-38 differs in the B/Lee/40 isolate at P5, this substitution may not reflect the original isolate. However, to establish whether CTL specific for 30-38 (RPIIRPATL) recognized this substitution, peptide 30-38 (K34) representing the B/Lee/40 sequence was synthesized, tested and recognized by the 30-38(R34) CTL line. The sequence (27, 28, 43 isolates differ by as much as 26% (6). Conservation of all of these peptide epitopes among sequenced isolates over time and over distinct viral lineages suggests that they are stable and therefore B type-specific CTL epitopes.
Are the conserved epitopes characterized intrinsically immunodominant or were they found because reactive CTL were disproportionately amplified by repeated viral exposure to different strains and in vitro stimulation? In dengue virus infections, cross-reactive CTL may be elicited during a secondary infection with a different serotype from the primary infection (44), but it is not known whether these CTL are protective. One of the first characteristics noticed about influenza type A-specific CTL was their cross-reactivity among different virus isolates (45, 46) . Subtype-and strain-specific CTL epitopes against influenza type A hemagglutinin have not been identified in polyclonal CTL responses, but only in cloned T cell populations (47). Subtype-and strain-specific CTL have not been identified against influenza type B proteins. Lower CTL frequencies for subtype-and strain-specific epitopes may make it difficult to detect such CTL. Whether CTL against conserved epitopes provide protection against both perforin-mediated and Fas ligand mechanisms (53). The
